Log In
BCIQ
Print this Print this
 

NGAL Test

  Manage Alerts
Collapse Summary General Information
Company BioPorto Diagnostics A/S
DescriptionIn vitro test that detects the lipocalin (LCN2; NGAL) biomarker produced in the kidneys
Molecular Target Lipocalin (NGAL) (LCN2)
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationRenal, Diagnostic
Indication DetailsDiagnose acute kidney injury (AKI)
Regulatory Designation
PartnerSiemens AG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/10/2012

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today